MedTrace Logo

Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer

NCT03774680 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-10-10

No results posted yet for this study

Summary

Due to the great toxicity of chemotherapeutic drugs to both the healthy and cancerous area, the efficient targeting could be of great benefit for a patient with advanced or metastatic tumors. Colorectal cells carry somatostatin receptors which make them a promising target for antitumor therapy since this would reduce side effects and increase drug delivery efficacy to the target site.

Conditions

Interventions

DRUG

Cetuximab nanoparticles

The active group will receive cetuximab in nanoparticles as an anti-microbial drug.

DRUG

Oral approved anticancer drug

The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.

Sponsors & Collaborators

  • Ahmed A. H. Abdellatif

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2020-02-01
Completion
2021-01-11

Countries

  • Egypt
  • Saudi Arabia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03774680 on ClinicalTrials.gov